Cognition Therapeutics (NASDAQ:CGTX) Issues Earnings Results

Cognition Therapeutics (NASDAQ:CGTX) issued its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01), Zacks reports. During the same quarter in the previous year, the business earned ($0.27) earnings per share.

Cognition Therapeutics Stock Up 1.0 %

Cognition Therapeutics stock traded up $0.00 during midday trading on Friday, hitting $0.43. 61,613 shares of the stock were exchanged, compared to its average volume of 2,481,307. The stock has a market capitalization of $17.91 million, a price-to-earnings ratio of -0.45 and a beta of 1.03. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95. The business’s 50-day moving average price is $0.59 and its 200-day moving average price is $0.55.

Analysts Set New Price Targets

CGTX has been the subject of a number of research reports. HC Wainwright raised their price target on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $1.00 to $1.50 in a report on Thursday, December 19th. Chardan Capital cut their target price on Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Friday. Finally, Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $7.70.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.